Comparison · NCT03436732-b96b0572
140 mcg/kg vs 100 mcg/kg: Number of Participants With Serious and Non-Serious Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 140 mcg/kg vs 100 mcg/kg: Number of Participants With Serious and Non-Serious Adverse Events. Trial comparisons, record NCT03436732-b96b0572. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03436732-b96b0572
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.301 | 0.954 | wilson | |
| Risk in group 2 | 1 | 0.207 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.25 | -0.699 | 0.569 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.426 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on 140 mcg/kg than on 100 mcg/kg | 4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 140 mcg/kg | Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses~LMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles~SEL-110: administered on day 1 of each cycle for up to 4 cycles | 3 | 4 | OG000 |
| Group 2 | 100 mcg/kg | Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses~LMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles~SEL-110: administered on day 1 of each cycle for up to 4 cycles | 1 | 1 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Serious and Non-Serious Adverse Events
- Description
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
- Time frame
- Date treatment consent signed to date off study, approximately one month and 25 days for the 100 mcg/kg Arm/Group, and 9 months and 28 days for the 140 mcg/kg Arm/Group.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
- NCT number
- NCT03436732
- Phases
- PHASE1
- Conditions
- Mesothelioma
- Interventions
- LMB-100, SEL-110
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2019-11-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03436732?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03436732-b96b0572